PEMOLINE TREATMENT OF DEFICIT SYMPTOMS IN SCHIZOPHRENIA

临床脑疾病科从事一系列临床研究 多巴胺激动剂的试验，以努力找到一些治疗 精神分裂症的缺陷症状。这项工作的动力来自于 从成像研究中获得的证据表明，通过增强大脑皮质 多巴胺能功能缺陷症状可能得到改善。 佩莫林是一种间接的多巴胺激动剂，长期用于治疗 儿童的注意力缺陷障碍。它有安全的记录 并且没有严重的毒性。在实验动物中，它是缺乏的 去甲肾上腺素能活动。此外，动物不会自行管理 毒品，这表明它具有很低的成瘾和滥用潜力。 这些特性使佩莫林有别于苯丙胺和 儿童最常用的多巴胺激动剂哌醋甲酯，以及 使佩莫林成为刺激皮质多巴胺的有吸引力的候选者 功能。 佩莫林在病人身上的公开试验令人鼓舞。正式的协议 正在为一项双盲临床研究做准备，以确认或拒绝 假设。

The Clinical Brain Disorders Branch is engaged in a series of clinical trials of dopamine agonists in an effort to find some treatment for the deficit symptoms of schizophrenia. The impetus for this work comes from evidence developed here from imaging studies that by enhancing cortical dopaminergic function deficit symptoms might be ameliorated. Pemoline is an indirect dopamine agonist long used in the treatment of attention deficit disorder in children. It has a track record of safety and lack of serious toxicity. In experimental animals it is devoid of noradrenergic activity. Additionally, animals will not self administer the drug, which suggests that it is has low addictive and abuse potential. These characteristics set pemoline apart from amphetamine and methylphenidate, the dopamine agonists most commonly used in children, and make pemoline an attractive candidate for stimulating cortical dopamine function. An open trial of pemoline in on patient was encouraging. A formal protocol is in preparation for a double blind clinical study to confirm or refuse the hypothesis.